Tacrocap

Tacrocap is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants.

Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited. Such inhibition preventsthe dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, gamma interferon, tumor necrosis factor-alpha, and granulocyte macrophage colony-stimulating factor. Tacrolimus also inhibits IL-2 receptor expression and nitric oxide release, induces apoptosis and production of transforming growth factor beta that can lead to immunosuppressive activity. The net result is the inhibition of T-lymphocyte activation and proliferation, as well as T-helper-cell-dependent B-cell response (i.e., immunosuppression).

If patients are able to tolerate oral therapy, the recommended oral starting doses should be initiated.

The initial dose of Tacrolimus capsules should be administered no sooner than 6 hours after transplantation in the liver, heart, or lung transplant patients.

In kidney transplant patients, the initial dose of Tacrolimus capsules may be administered within 24 hours of transplantation but should be delayed until renal function has recovered.

Initial Oral Tacrolimus Capsules Dosage Recommendations and Whole Blood Trough Concentration Range in Adults:

Adult Patients

Initial oral dosage of Tacrolimus. Daily doses should be administered every 12 hours

Whole blood trough concentration range

Kidney transplant patients: In combination with azathioprine In combination with MMF/IL-2 receptor antagonist

0.2 mg/kg/day 0.1 mg/kg/day

month 1-3: 7-20 ng/mL month 4-12: 5-15 ng/mL month 1-12: 4-11 ng/mL

Liver transplant patients: With corticosteroids only

0.10-0.15 mg/kg/day

month 1-12: 5-20 ng/mL

Heart transplant patients: With azathioprine or MMF

0.075 mg/kg/day

month 1-3: 10-20 ng/mL month ≥4: 5-15 ng/mL

Lung Transplant patients: With azathioprine or MMF

0.075 mg/kg/day

Month 1-3: 10-15 ng/mL Month 4-12: 8-12 ng/mL

Note : In lung transplantation, cystic fibrosis patients may have a reduced bioavailability of orally administered tacrolimus resulting in the need for higher doses to achieve target tacrolimus trough concentrations. Monitor tacrolimus trough concentrations and adjust the dose accordingly. Initial Oral Tacrolimus Capsules Dosage Recommendations and Whole Blood Trough Concentration Range in Childrens:

Pediatric Patients

Initial oral dosage of Tacrolimus. Daily doses should be administered every 12 hours.

• Whole blood trough concentration range
• Kidney transplant patients
• 0.3 mg/kg/day
• Month 1-12: 5-20 ng/mL
• Liver transplant patients
• 0.15-0.2 mg/kg/day
• Month 1-12: 5-20 ng/mL
• Heart transplant patients
• 0.3 mg/kg/day
• Month 1-12: 5-20 ng/mL
• Lung transplant patients
• 0.3 mg/kg/day

Week 1-2: 10-20 ng/mL Week 2 to Month 12: 10-15 ng/mL

Note : In lung transplantation, cystic fibrosis patients may have a reduced bioavailability of orally administered tacrolimus resulting in the need for higher doses to achieve target tacrolimus trough concentrations. Monitor tacrolimus trough concentrations and adjust the dose accordingly.

Mycophenolic Acid Products : Can increase MPA exposure after crossover from cyclospo-rine to Tacrocap; monitor for MPA-related adverse reactions and adjust MMF or MPA dose as needed.

Nelfinavir and Grapefruit Juice : Increased tacrolimus concentrations via CYP3A inhibition; avoid concomitant use.

CYP3A Inhibitors : Increased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed.

CYP3A4 Inducers : Decreased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed.

Therapeutic drug monitoring and dose reduction for Tacrocap should be considered when Tacrocap is co-administered with cannabidiol.

Hypersensitivity to tacrolimus or HCO-60 (polyoxyl 60 hydrogenated castor oil).

The most common adverse reactions (≥15%) were abnormal renal function, hypertension, diabetes mellitus, fever, CMV infection, tremor, hyperglycemia, leukopenia, infection, anemia, bronchitis, pericardial effusion, urinary tract infection, constipation, diarrhea, headache, abdominal pain, insomnia, paresthesia, peripheral edema, nausea, hyperkalemia, hypomag-nesemia, and hyperlipemia.

Pregnancy: Can cause fetal harm. Advise pregnant women of the potential risk to the fetus.

Not Interchangeable with Extended-Release Tacrocap Products- Medication Errors : Instruct patients or caregivers to recognize the appearance of Tacrocap capsules. New Onset Diabetes After Transplant : Monitor blood glucose. Nephrotoxicity (acute and/or chronic) : Reduce the dose; use caution with other nephrotoxic drugs. Neurotoxicity : Including risk of Posterior Reversible Encephalopathy Syndrome (PRES); monitor for neurologic abnormalities; reduce or discontinue Tacrocap. Hyperkalemia : Monitor serum potassium levels. Consider carefully before using with other agents also associated with hyperkalemia. Hypertension : May require antihypertensive therapy. Monitor relevant drug-drug interactions. Anaphylactic Reactions with IV formulation : Observe patients receiving Tacrocap injection for signs and symptoms of anaphylaxis. Not recommended for use with sirolimus : Not recommended in liver and heart transplant due to increased risk of serious adverse reactions. Myocardial Hypertrophy : Consider dose reduction/discontinuation. Immunizations : Avoid live vaccines. Pure Red Cell Aplasia : Consider discontinuation of Tacrocap. Thrombotic Microangiopathy, Including Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura : May occur, especially in patients with infections and certain concomitant medications.

Acute overdosages of up to 30 times the intended dose have been reported. Acute overdosage was sometimes followed by adverse reactions consistent with those reported with the use of Tacrocap including tremors, abnormal renal function, hypertension, and peripheral edema. The oral use of activated charcoal has been reported in treating acute overdoses, but experience has not been sufficient to warrant recommending its use. General supportive measures and treatment of specific symptoms should be followed in all cases of overdosage.

Store below 30°C, dry place, away from light and moisture. Keep out of the reach of children.